Ribometrix
PrivateLast Round
Strategic
Jan 6, 2021
Total Funding Raised
$45.79M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Ribometrix is a biotechnology company that develops small molecule therapeutics designed to modulate RNA biology for the treatment of human diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ribometrix Comparables
Compare Ribometrix with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Arrakis Therapeutics | 93% | |
| Expansion Therapeutics | 90% | |
| Base4 Biotechnology | 89% |
Ribometrix Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Jan 6, 2021 | ||||
| Strategic | Sep 30, 2019 | ||||
| Series A Extension | Sep 27, 2019 | ||||
| Series A | Nov 13, 2018 | ||||
| Seed | Oct 31, 2017 |
Key People
Founding team and executive leadership
Ribometrix Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Health Investors | Series A, Series A Extension, Seed |
| A. M. Pappas & Associates | Series A |
| MP Healthcare Venture Management | Seed, Series A |
| NIH RADx | Grant |
| Genentech | Strategic |
| M Ventures | Series A |
| Hatteras Venture Partners | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 81% MoM.
- Jan 9, 2025
Katie Warner appointed as new Chief Scientific Officer.
Ribometrix Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Ribometrix's valuation, stock price, and market status.
Is Ribometrix a public or private company?
Ribometrix is a private company.
What is the current stock price of Ribometrix?
Ribometrix is a private company with no public stock price. No recent secondary market data is available.
How much is Ribometrix worth (valuation)?
Valuation information for Ribometrix is not publicly available.
Can I buy Ribometrix stock?
Ribometrix shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Ribometrix's last funding round?
Ribometrix's most recent funding round was Strategic on January 6, 2021.
Who are the main investors in Ribometrix?
Key investors in Ribometrix include SV Health Investors, NIH RADx, Genentech, M Ventures, Hatteras Venture Partners.
Will Ribometrix IPO soon?
No public IPO plans have been announced for Ribometrix.
How can I track Ribometrix secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Ribometrix's secondary market activity and sign up for updates.